138 related articles for article (PubMed ID: 37467457)
1. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Jang A; Lanka SM; Jaeger EB; Lieberman A; Huang M; Sartor AO; Mendiratta P; Brown JR; Garcia JA; Farmer T; Sudhaman S; Mahmood T; Pajak N; Calhoun M; Dutta P; ElNaggar A; Liu MC; Barata PC
JCO Precis Oncol; 2023 Jul; 7():e2300131. PubMed ID: 37467457
[TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
3. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review.
Al-Showbaki L; Wilson B; Tamimi F; Molto C; Mittal A; Cescon DW; Amir E
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792122
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract][Full Text] [Related]
5. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
[TBL] [Abstract][Full Text] [Related]
7. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
8. Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer.
Tan Q; Chi Y; Su M; Zhou J; Zhou D; Zheng F; Man X; Sun S; Huang J; Li H
Front Genet; 2023; 14():1125970. PubMed ID: 37007962
[No Abstract] [Full Text] [Related]
9. Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis.
Bui NQ; Nemat-Gorgani N; Subramanian A; Torres IA; Lohman M; Sears TJ; van de Rijn M; Charville GW; Becker HC; Wang DS; Hwang GL; Ganjoo KN; Moding EJ
Clin Cancer Res; 2023 Jul; 29(14):2612-2620. PubMed ID: 37130154
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
11. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
12. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Weber S; van der Leest P; Donker HC; Schlange T; Timens W; Tamminga M; Hasenleithner SO; Graf R; Moser T; Spiegl B; Yaspo ML; Terstappen LWMM; Sidorenkov G; Hiltermann TJN; Speicher MR; Schuuring E; Heitzer E; Groen HJM
JCO Precis Oncol; 2021 Nov; 5():1540-1553. PubMed ID: 34994642
[TBL] [Abstract][Full Text] [Related]
14. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
Chehrazi-Raffle A; Muddasani R; Dizman N; Hsu J; Meza L; Zengin ZB; Malhotra J; Chawla N; Dorff T; Contente-Cuomo T; Dinwiddie D; McDonald BR; McDaniel T; Trent JM; Baehner FL; Murtaza M; Pal SK
JCO Precis Oncol; 2023 Apr; 7():e2200543. PubMed ID: 37027813
[TBL] [Abstract][Full Text] [Related]
18. Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies.
Zhang S; Brazel D; Kumar P; Schafer LN; Eidenschink B; Senthil M; Dayyani F
J Gastrointest Oncol; 2021 Dec; 12(6):2643-2652. PubMed ID: 35070394
[TBL] [Abstract][Full Text] [Related]
19. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Zhang Q; Luo J; Wu S; Si H; Gao C; Xu W; Abdullah SE; Higgs BW; Dennis PA; van der Heijden MS; Segal NH; Chaft JE; Hembrough T; Barrett JC; Hellmann MD
Cancer Discov; 2020 Dec; 10(12):1842-1853. PubMed ID: 32816849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
